Tian Huang

发表

Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies

X. Kong, Yongxiang Xia, Zehua Jin, 2022, International journal of biological sciences.

Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study

Chen Wu, X. Kong, Wenzhou Ding, 2022, Frontiers in Oncology.

Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma

X. Kong, Yongxiang Xia, Weiwei Tang, 2022, Frontiers in Immunology.

Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy

Yongxiang Xia, Weiwei Tang, Jinyu Zhang, 2022, Journal for ImmunoTherapy of Cancer.

Midazolam exhibits antitumour and enhances the efficiency of Anti-PD-1 immunotherapy in hepatocellular carcinoma

Xiongxiong Pan, Chengyu Lv, Xian Li, 2022, Cancer Cell International.

GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway

Yongxiang Xia, Weiwei Tang, Ziyi Chen, 2023, Journal for ImmunoTherapy of Cancer.

Targeting the metabolism of tumor-infiltrating regulatory T cells.

Ling Lu, Tian Huang, J. Gu, 2023, Trends in immunology.

CHSY1 promotes CD8+ T cell exhaustion through activation of succinate metabolism pathway leading to colorectal cancer liver metastasis based on CRISPR/Cas9 screening

Weiwei Tang, Guoqiang Sun, Guangshun Sun, 2023, Journal of Experimental & Clinical Cancer Research.

Single-cell RNA-sequencing atlas reveals an FABP1-dependent immunosuppressive environment in hepatocellular carcinoma

Yongxiang Xia, Weiwei Tang, Li Liu, 2023, Journal for ImmunoTherapy of Cancer.

Metabolomics reveals ascorbic acid inhibits ferroptosis in hepatocytes and boosts the effectiveness of anti-PD1 immunotherapy in hepatocellular carcinoma

Guoqiang Sun, Tian Huang, H. Cao, 2024, Cancer cell international.